Creator notes – Probiotics For Gi Issues
The demonstration that immune and epithelial cells can discriminate between totally different microbial species has prolonged our understanding of the actions of probiotics past easy barrier and antimicrobial ideas. A number of probiotic mechanisms of motion, relative to inflammatory bowel illness, have been elucidated: (1) aggressive exclusion, whereby probiotics compete with microbial pathogens for a restricted variety of receptors current on the floor epithelium; (2) immunomodulation and/or stimulation of an immune response of gut-associated lymphoid and epithelial cells; (3) antimicrobial exercise and suppression of pathogen development; (4) enhancement of barrier perform; and (5) induction of T cell apoptosis within the mucosal immune compartment. The unraveling of those mechanisms of motion has led to new help for the usage of probiotics within the administration of medical inflammatory bowel illness. Although stage 1 proof now helps the therapeutic use of probiotics within the therapy of postoperative pouchitis, solely ranges 2 and three proof is at present obtainable in help of the usage of probiotics within the therapy of ulcerative colitis and Crohn’s illness. Nonetheless, one vital and constant discovering has emerged throughout the course of analysis prior to now yr: not all probiotic micro organism have related therapeutic results. Rigorously designed, managed medical trials are very important to analyze the unresolved points associated to efficacy, dose, period of use, single or multi-strain formulation, and the concomitant use of prebiotics, synbiotics, or antibiotics.
The mammalian intestinal tract is house to a fancy and numerous society of pathogenic and nonpathogenic micro organism. Traditionally, microbial analysis has targeted on the mechanisms by which pathogenic micro organism exert their detrimental results. Nonetheless, more moderen analysis has supplied a glimpse into the health-related roles performed by indigenous, nonpathogenic microorganisms (probiotics). Probiotics, prebiotics, and synbiotics are transferring into the mainstream of medical remedy. This new acceptance has been facilitated by our elevated understanding of the mechanisms of motion by which these brokers exert their useful results, by the event of molecular strategies for analyzing and figuring out advanced bacterial communities inside mammalian intestines, and by the development of well-designed, managed medical trials of the results of probiotics on inflammatory bowel illness (IBD). Quite a lot of overview articles have been printed over the past 2 years outlining the efficacy of probiotics, prebiotics, and synbiotics within the therapy of IBD. 1,–19
The Function Micro organism Play in Inflammatory Bowel Illness
A number of traces of experimental proof implicate enteric flora within the pathogenesis of ulcerative colitis and Crohn’s illness. First, the incidence of irritation within the case of those problems is biggest within the space with the best concentrations of luminal micro organism. Second, the continuity of the fecal stream has been implicated in illness exercise, and interruption of this stream is related to illness enchancment. Third, intestinal irritation and mucosal ulceration might be induced by direct instillation of fecal contents from an infected intestine right into a non-inflamed intestine of inclined people. Fourth, there’s rising proof that means there’s a genetically decided lack of immunologic tolerance to commensal micro organism within the case of sufferers who’ve IBD. Fifth, proof pointing to the interplay of genes, immunity, and micro organism has emerged throughout the previous half-decade, and the proof is especially noticeable within the case of a collection of sporadic, engineered, and genetically decided animal fashions of IBD. In every of those fashions, enteric flora is required for the induction of the inflammatory course of, whatever the underlying genetic predisposition or immunologic effector mechanism defect. The invention of the position enteric flora play as a part of a standard pathway to medical IBD has led to renewed curiosity in, and growing scientific evaluation of, probiotic modification of the luminal bacterial setting for therapeutic causes.
Mechanisms of Motion of Probiotic Micro organism in Inflammatory Bowel Illness
It’s clear that vital variations exist between probiotic bacterial species and strains. Earlier analysis on probiotics has targeted on their security and skill to outlive gastrointestinal transit relative to their use within the agriculture and meals business. Nonetheless, throughout the previous a number of years, vital advances have been made in understanding the mechanisms of motion of particular person strains as they relate to the pathophysiology of IBD. An understanding of those mechanisms of motion will subsequently allow improvement of definitive standards for choice of probiotic strains for particular medical indications. It should additionally permit for the willpower of optimum doses, timing of administration, and potential synergy between bacterial species.
At present, useful results of probiotic micro organism could also be broadly categorized into two most important classes: (1) these results arising because of exercise within the massive gut associated to colonization and inhibition of pathogen development and (2) these results associated to enhancement of the host immune response and barrier perform via interactions with epithelial and immune cells inside each the small and huge gut. It’s turning into clear that the functioning of the immune system at each a systemic and a mucosal stage might be modulated by bacterial strains within the gut. Immune cells are regularly sampling and responding to intestinal microflora. 20 As effectively, totally different bacterial strains can sign via pattern-recognition receptors, thereby modulating varied intracellular signaling pathways. 21,22 Lively constituents of micro organism that manipulate the mucosal immune system embody enzymes 23; secreted protein elements 24; bacterial formulated peptides resembling N-formyl-methionine-leucine-phenylalanine (fMLP) and lipopolysac-charide (LPS) 22,25; and peptidoglycan cell wall constituents together with the muramyl dipeptide (MDP) MurNAc-L-Ala-D-isoGln 26,27, gamma-D-glutamyl-meso-diaminopimelic acid (iE-DAP), 28 and bacterial deoxyribonucleic acid (DNA). 29,–31
There are at present 5, doubtless interrelated, probiotic mechanisms of motion relative to remedy for IBD: (1) receptor competitors, whereby probiotics compete with microbial pathogens for a restricted variety of receptors current on the floor epithelium; (2) immunomodulation and/or stimulation of immune perform of gut-associated lymphoid and epithelial cells; (3) probiotic-induced suppression of pathogen development via launch of antimicrobial elements resembling lactic and acetic acid, hydrogen peroxide, and bacteriocins; (4) probiotic-induced enhancement of mucosal barrier perform; and (5) induction of T-cell apoptosis within the lamina propria (Fig. 1).
Determine 1. Open in new tabDownload slide Mechanisms of motion of probiotics in remedy for inflammatory bowel illness. 5, doubtless interrelated, probiotic mechanisms of motion relative to inflammatory bowel illness (IBD) are illustrated: (1) aggressive exclusion, whereby probiotics compete with microbial pathogens for a restricted variety of receptors current on the floor epithelium; (2) immunomodulation and/or stimulation of an immune response; (3) probiotic-induced antimicrobial exercise and suppression of pathogen development via launch of antimicrobial elements resembling lactic and acetic acid, hydrogen peroxide, defensins, and bacteriocins; (4) probiotic-induced enhancement of barrier exercise via mucin manufacturing and secretion; and (5) induction of T-cell apoptosis within the mucosal immune compartment.
Determine 1. Open in new tabDownload slide Mechanisms of motion of probiotics in remedy for inflammatory bowel illness. 5, doubtless interrelated, probiotic mechanisms of motion relative to inflammatory bowel illness (IBD) are illustrated: (1) aggressive exclusion, whereby probiotics compete with microbial pathogens for a restricted variety of receptors current on the floor epithelium; (2) immunomodulation and/or stimulation of an immune response; (3) probiotic-induced antimicrobial exercise and suppression of pathogen development via launch of antimicrobial elements resembling lactic and acetic acid, hydrogen peroxide, defensins, and bacteriocins; (4) probiotic-induced enhancement of barrier exercise via mucin manufacturing and secretion; and (5) induction of T-cell apoptosis within the mucosal immune compartment.
It stays to be established which potential mechanism(s) relate to the therapy of IBD and the way the pathophysiology of medical illness is altered via consumption of probiotics. Nonetheless, it’s clear from experimental fashions that probiotic strains differ drastically of their mechanisms of motion, and {that a} single mechanism of motion is unlikely to be answerable for their medical results (Desk 1). Along with particular interactions between probiotic micro organism and host immune cells, microbe-microbe interactions additionally exist. This might clarify a few of the various outcomes noticed throughout the totally different medical trials. One of the extensively accepted theories of IBD is that acute and persistent irritation outcomes from an interplay between susceptibility genes, luminal microflora, and a dys-regulated immune system. It’s doubtless that future analysis will end result within the identification of medical phenotypes in sufferers with IBD that reply to probiotic remedy and that particular strains will likely be characterised to ensure that a focused therapeutic strategy to happen.
Pouchitis
Pouchitis
is a nonspecific irritation of the ileal reservoir and is a standard complication following pouch surgical procedure for ulcerative colitis. Its medical frequency relies upon largely on the period of the follow-up however is roughly 50% after 10 years. The reason for pouchitis stays unknown. Nonetheless, current research have demonstrated lowered counts of lactobacilli and bifidobacteria throughout the pouch. This implies that this syndrome could also be the results of altered luminal microflora. 32 Although the vast majority of sufferers with pouchitis reply to therapy with antimicrobial brokers, roughly 10% of sufferers expertise recurrent or refractory illness. It was via well-designed medical trials in these sufferers with pouchitis that the therapeutic potential of probiotics for IBD was initially demonstrated (Desk 2).
Upkeep of Antibiotic-Induced Remission of
Pouchitis
Gionchetti et al 33 performed a randomized, double-blind, placebo-controlled trial in 40 sufferers with acute lively pouchitis. These sufferers had been in medical and endoscopic remission [with a score of zero in the clinical and endoscopic portion of the pouchitis disease activity index (PDAI)] after 1 month of antibiotic therapy with ciprofloxacin (1 g each day) plus rifaximin (2 g each day). They had been then randomized to obtain VSL#3 (two 3 g sachets as soon as each day) [VSL Pharmaceuticals Inc., Fort Lauderdale, Florida, USA; 6 g per day containing 1.8 × 1012 viable lyophilized colony forming units (cfu) per day of 4 strains of Lactobacillus (Lactobacillus casei, Lactobacillus plantarum, Lactobacillus acidophilus, and Lactobacillus delbrueckii subsp. Bulgaricus), 3 strains of Bifidobacterium (Bifidobacterium longum, Bifidobacterium breve, and Bifidobacterium infantis), and 1 strain of Streptococcus salivarius subsp. thermophilus] or placebo for 9 months. Of the 20 sufferers who obtained placebo, 100% had relapses throughout the 9-month interval. In distinction, 17 of the 20 sufferers (85%) who obtained VSL#3 had been nonetheless in remission with a PDAI of zero (eg, regular) after 9 months (p < 0.001). Moreover, 100% of the sufferers receiving VSL#3 had relapses inside 4 months after the VSL#3 therapy was stopped. These dramatic outcomes supplied the primary conclusive proof that, given the proper dose and mixture, probiotics can play a serious therapeutic position within the administration of IBD. These authors additionally demonstrated that in sufferers handled with VSL#3, fecal concentrations of lactobacilli, bifidobacteria, and Streptococcus salivarius elevated considerably in contrast with concentrations current earlier than and after therapy. No adjustments had been recognized in concentrations of Bacteroides, coliforms, clostridia, enterococci, and complete aerobes and anaerobes in contrast with basal ranges. As soon as the VSL#3 was withdrawn, fecal concentrations of lactobacilli, bifidobacteria, and Streptococcus salivarius fell again to basal ranges. Not too long ago, the outcomes with VSL#3 within the upkeep of antibiotic-induced remission have been replicated by a separate analysis group in a double-blind, placebo-controlled examine. 34 This group equally induced remission (PDAI of zero) in sufferers with lively pouchitis with 4 weeks of mixed metronidazole and ciprofloxacin. Sufferers had been then randomized to obtain both VSL#3 (1.8 × 1012 cfu as soon as each day) or placebo for 1 yr. The one variations on this examine, relative to that of the Gionchetti examine outlined above, 33 had been that the VSL#3 was given as soon as each day relatively than twice each day, and follow-up was 12 months relatively than 9 months, respectively. Remission was maintained at 1 yr in 17 sufferers (85%) on VSL#3 and in 1 affected person (6%) on placebo. These outcomes with the multispecies probiotic combination (VSL#3) had been just about an identical to these of the Gionchetti examine. It additionally served to verify the effectiveness of this particular probiotic routine within the administration of pouchitis. It is very important word that in each of those medical trials, the amount of VSL#3 was greater than that utilized in later research and in present medical apply. Remedy of Acute Lively
Pouchitis
In distinction, Kuisma et al 35 didn’t exhibit a therapeutic impact of probiotics in acute lively pouchitis with a single-strain Lactobacillus rhamnosus GG formulation. On this randomized, double-blind, placebo-controlled trial, 44 topics with acute infected pouches (PDAI of roughly 8; vary 5 to 13) had been randomized to obtain Lactobacillus rhamnosus GG (4 × 1010 cfu each day in two equal doses) or placebo for 3 months. No variations had been discovered within the imply pretreatment or posttreatment PDAI scores between the 2 therapy teams. No vital adjustments had been seen within the concentrations of cardio or anerobic micro organism within the pouch. Nonetheless, there was a pattern towards greater fecal concentrations of complete lacto-bacilli. Nonetheless, solely 40% of examine topics had been colonized with Lactobacillus GG. The reason for the destructive therapeutic results on this medical trial with Lactobacillus rhamnosus GG stays to be decided. These outcomes exhibit the requirement for administration of a number of probiotic micro organism concurrently (as are current in VSL#3) and/or the next probiotic dose, or the necessity for pretreatment with antibiotics to induce remission previous to the probiotic remedy.
Laake et al 36 used an open, nonrandomized therapy with sufferers performing as their very own controls. Ten topics with acute lively pouchitis had been handled with 500 g of the dairy product Cultura (TINE Dairies BA, Oslo, Norway; 100 g accommodates 1 × 1010 cfu of each Lactobacillus acidophilus and Bifidobacterium lactis, 3.2 g protein, 1.5 g fats, and 4.3 g carbohydrate). Cultura supplied a each day consumption of each lactobacilli and bifidobacteria (5 × 1010 cfu) for 4 weeks. Seven of 10 sufferers had a lowered endoscopic rating (utilizing the endoscopic portion of the PDAI) after intervention and a 50% discount in median values from 3.0 to 1.5 (p = 0.016). Curiously, the histologic and laser Doppler flowmetry (LDF) scores, as a measure of irritation, didn’t change with probiotic remedy. Thus, it’s potential that the development in endoscopic rating represents the bias of a single observer, nonblinded, endoscopic evaluation in an open-label medical trial. Microbiological evaluation of the pouch confirmed that throughout the probiotic administration, 80% of sufferers had extra lactobacilli. Nonetheless, the variations didn’t attain statistical significance, and 1 week after the probiotic was stopped, the degrees of lactobacilli returned to basal ranges. Much like the examine by Kuisma et al, 35 therapy of acute lively pouchitis with probiotics didn’t confer a constructive therapeutic impact.
Postoperative Prevention of
Pouchitis
To look at additional the spectacular medical impact of VSL#3 within the administration of pouchitis, the Italian group of Gionchetti et al 37 prolonged their observations to the usage of VSL#3 within the postoperative prevention of pouchitis. They carried out a randomized, double-blind, placebo-controlled trial the place VSL#3 (9 × 1011 micro organism per day) or placebo was administered for 12 successive months, starting inside 1 week after ileostomy closure and pouch formation. PDAI was assessed at 1, 3, 6, 9, and 12 months. Of the 20 sufferers randomized to obtain VSL#3, 90% had regular pouch (with a PDAI of zero) after 1 yr. In distinction, solely 60% of sufferers randomized to obtain placebo had been in remission after 1 yr (p < 0.05). As soon as once more, in sufferers handled with VSL#3, there was no vital change in concentrations of Bacteroides, coliforms, clostridia, or enterococci within the pouches in contrast with the basal ranges. In distinction, fecal concentrations of lactobacilli, bifidobacteria, and Streptococcus thermophilus had been considerably elevated in contrast with concentrations at baseline. Within the placebo group, fecal concentrations of all species evaluated remained much like that earlier than beginning therapy. 37
Crohn’s Illness
Relative to the research of probiotics in pouchitis, there are only a few randomized, managed medical trials utilizing probiotics in Crohn’s illness. The outcomes of the printed medical trials with probiotics within the therapy of Crohn’s illness are proven in Desk 3, for therapy of acute lively illness;Desk 4, for upkeep of medical-induced remission; and Desk 5, for upkeep of surgical-induced remission.
Remedy of Acute Lively Illness
Gupta et al 38 performed an open-label, pilot trial in youngsters with mildly to reasonably lively illness [Pediatric
Crohn’s Disease
Activity Index (PCDAI) > 10], along with concomitant remedy with prednisone and immunomodulatory brokers. Sufferers obtained a 6-month, open-label analysis of Lactobacillus GG (2 × 1010 cfu per day). 4 sufferers had been enrolled on this pilot mission. There was vital enchancment within the PCDAI 1 week after starting Lactobacillus GG. This enchancment was sustained all through the examine, with the median PCDAI 73% decrease than baseline. In three sufferers, it was potential to taper the dose of steroids whereas they had been receiving Lactobacillus GG. Intestinal permeability, as decided by a double sugar permeability take a look at, improved considerably with the Lactobacillus GG. Three sufferers had relapse of their Crohn’s illness inside 4–12 weeks of discontinuation of the Lactobacillus GG.
An open-label trial utilizing the probiotic Lactobacillus salivarius UCC118 has additionally yielded encouraging ends in treating acute lively Crohn’s illness. 39 Sufferers with lively illness got the chance to obtain the probiotic Lactobacillus salivarius (1 × 1010 cfu per day) as a substitute of corticosteroids. Twenty-five sufferers enrolled, 4 dropped out with illness exacerbation, and two required corticosteroid remedy. Nineteen sufferers (76%) accomplished 3 months of therapy and had been in a position to keep away from different remedy. As well as, CDAI in these sufferers fell from a imply of 217 at entry to a imply of 150 at 3 months (p < 0.05). Controlled trials using this probiotic are currently underway. Maintenance of Medical-Induced Remission Malchow et al 40 investigated the role of Escherichia coli (E. coli) Nissle 1917 (Mutaflor; Ardeypharm, Herdecke, Germany) in a randomized, double-blind, placebo-controlled pilot study of corticosteroid-induced remission. Twenty-eight patients with active colonic Crohn's disease (CDAI > 150) had been handled with prednisolone (60 mg per day) in an ordinary tapering routine over 14 weeks. Initially of the prednisolone remedy, sufferers had been randomized to obtain both E. coli Nissle 1917 (5 × 109 cfu as soon as each day) or placebo for 1 yr. Utilizing intent to deal with evaluation, the preliminary remission price was 92% within the prednisolone and placebo group and 75% within the prednisolone and E. coli group (p = ns). Utilizing per protocol evaluation, the outcomes had been 92% and 86%, respectively. As soon as remission was achieved and the prednisilone had been tapered to zero, the proportion of sufferers that remained in remission on the finish of 1 yr was 70% within the E. coli Nissle 1917 handled group versus 30% within the placebo handled group (p = ns).
Guslandi et al 41 examined the position of Saccharomyces boulardii within the upkeep of remission in 32 sufferers with Crohn’s illness. These sufferers had been in a medically induced remission for no less than 3 months (CDAI < 150). On the time of entry into the examine, the sufferers had been off all medicines for no less than 3 months. Sufferers had been then randomized to obtain mesalamine (Pentasa; Ferring Prescribed drugs, Copenhagen, Denmark) (3 g each day in three divided doses) or mesalamine (Pentasa) (2 g each day in two divided doses) plus a preparation of Saccharomyces boulardii (1 g each day) for six months. Scientific remission at 6 months was noticed in 10 of the 16 sufferers on mesalamine upkeep and in 15 out of sixteen sufferers receiving mesalamine Saccharomyces boulardii (p = 0.04). Regardless of this encouraging end result, no additional research with Saccharomyces boulardii have been printed. Upkeep of Surgical-Induced Remission Prantera et al 42 carried out a randomized, double-blind, single-centered, placebo-controlled upkeep of surgical-induced remission trial. Forty-five sufferers in medical remission (CDAI < 150) had been randomized to obtain both Lactobacillus GG casei subspecies rhamnosus (1.2 × 1010 cfu each day) or placebo inside 10 days following surgical resection of their Crohn's illness. After 52 weeks of therapy, 15 sufferers (83%) handled with Lactobacillus GG and 17 sufferers (89%) handled with placebo remained in medical remission (p = 0.948). In distinction, endoscopic remission was recognized in 6 sufferers (40%) within the Lactobacillus GG group, in contrast with 11 sufferers (65%) within the placebo group (p = 0.243). Contemplating the success of Lactobacillus GG within the prevention of antibiotic-, Clostridium difficile-, and childhood-diarrhea, the rationale for these marked destructive ends in the upkeep of surgical-induced remission in Crohn's illness stays speculative. It might be that, much like the outcomes seen with pouchitis, therapy with sure single species of probiotics is much less efficient than mixture brokers. Whether or not this represents particular person species choice or amount of micro organism delivered and/or colonized stays to be decided. Campieri et al 43 reported, in summary type, {that a} mixture of antibiotic and the probiotic combination (VSL#3) therapy was efficacious in prevention of the postoperative recurrence of Crohn's illness when put next with mesalamine. Forty sufferers had been randomized to obtain both rifaximin (1.8 g per day) for 3 months adopted by VSL#3 (6 × 1011 cfu per day) for 9 months, or mesalamine (4 g per day) for 12 months. After 1 yr, the antibiotic/VSL#3 group had an endoscopic remission price of 80% in contrast with 60% within the mesalamine group (p < 0.05). Curiously, these endoscopic remission charges at 1 yr with an antibiotic adopted by VSL#3 are related to people who have beforehand been described with metronidazole alone. 44
Ulcerative Colitis
The outcomes of the printed medical trials with probiotics within the therapy of ulcerative colitis are proven in Desk 6 for therapy of acute lively illness and in Desk 7 for upkeep of remission.
Remedy of Acute Lively Illness
In 1999, Rembacken et al 45 performed a single-center, randomized, double-dummy examine inspecting 116 sufferers with lively ulcerative colitis, assessing each therapy of acute lively illness and upkeep of remission. Sufferers had been randomized to mesalamine (Asacol; Procter & Gamble Prescribed drugs, Inc., Egham, Surrey, UK) (1.2 g per day in three divided doses) or nonpathogenic E. coli Nissle 1917 (1 × 1011 cfu per day in two divided doses). At entry into the examine, all sufferers got an preliminary 1-week course of oral gentamicin (80 mg thrice each day) to suppress their native E. coli flora. Together with the examine, probiotic or mesalamine sufferers had been additionally permitted to obtain therapy with tapering prednisolone for average and extreme illness and rectal hydrocortisone enemas for proctitis for 3 months to induce remission. After getting into into remission, sufferers had been maintained on both mesalamine or E. coli for as much as 12 months. Forty-four sufferers (75%) within the mesalamine group and 39 sufferers (68%) within the E. coli group attained remission. The median time to remission was related in each teams. On the finish of 12 months, 25% of sufferers within the mesalamine group and 26% of sufferers within the E. coli group maintained remission. The median period of remission was related in each teams. The authors counsel that therapy with this nonpathogenic E. coli has an equal impact to mesalamine in sustaining remission. Nonetheless, the examine was not powered for equivalence, and the remission charges at 1 yr had been near historic placebo charges.
Not too long ago, Fedorak et al 46 evaluated the efficacy of VSL#3 in an open-label, two-center trial with 30 sufferers with lively delicate to average ulcerative colitis. These sufferers had failed mesalamine remedy and had been handled with VSL#3 (1.2 × 1012 cfu each day in two divided doses) for six weeks. Remission, as decided by an ulcerative colitis medical rating of <3, was achieved in 63% of VSL#3-treated sufferers. Response, as decided as an ulcerative colitis medical rating of a lower of ≥3 and a ultimate worth of ≥3, was achieved in 23% of VSL#3-treated sufferers. No response was present in 13% of the handled sufferers. This represents a big enchancment in a tough to deal with inhabitants. A randomized, managed trial is underway to verify these outcomes. Guslandi et al 47 studied 25 sufferers with a medical flare of their ulcerative colitis of a light to average diploma, based on Truelove and Witts' standards. The sufferers had been on upkeep mesalamine (3 g per day) for no less than 3 months. Solely sufferers who had a historical past of poorly tolerating corticosteroids had been permitted to enter the examine. On this open-label trial, sufferers obtained Saccharomyces boulardii (750 mg per day in three divided doses) for 4 weeks whereas their ongoing mesala-mine was continued. Scientific illness exercise rating, earlier than and after probiotic remedy, was decided by the Rachmilewitz ulcerative colitis exercise index; it's calculated on the idea of stool frequency, blood within the stool, basic situation, fever, belly ache, erythrocyte sedimentation price, and hemoglobin values. A major discount within the ulcerative colitis exercise index rating was noticed on the finish of therapy (p < 0.05), and remission (a illness exercise rating ≤ 5) was achieved in 17 of 25 sufferers (68%). 47 Curiously, the remission price on this pilot examine is remarkably much like the remission charges described above for E. coli Nissle 1917 and VSL#3. A current intriguing examine by Borody et al, 48 barely outdoors of the true probiotic realm, used fecal bacteriotherapy (fecal enemas) in six sufferers. These sufferers had failed most customary remedy for ulcerative colitis, together with a number of programs of corticosteroids and immunosuppressive remedy. Fecal enemas had been ready contemporary (in regular saline) from wholesome grownup donors, nominated by the sufferers and administered as soon as each day for five consecutive days as enemas (retained for six–8 hours). Along with the fecal enemas, sufferers had been prescribed a high-fiber food regimen in try and stimulate proliferation of infused micro organism. In a collection of case studies, the authors doc that these six sufferers had been in a position to withdraw all concurrent ulcerative colitis treatment roughly 4–6 weeks following completion of the fecal enema remedy. In 1–13 years of follow-up, there was no medical, colonoscopic, or histologic proof of ulcerative colitis recurrence in any affected person, even if no upkeep remedy has been used. 48 Clearly, these outcomes are dramatic and worthy of additional investigation each from a pathogenesis in addition to a therapeutic standpoint. Upkeep of Remission In 1997, Kruis et al 49 examined 120 sufferers with inactive ulcerative colitis. These sufferers had been included in a double-blind, double-dummy examine evaluating mesalamine (Salofalk; Axcan Pharma Inc., Houdan, France) (1.5 g per day in three divided doses) to an oral preparation of E. coli Nissle 1917 (5 × 1010 cfu per day as a single dose) for 3 months. Scientific remission was outlined by the Rackmilewitz illness exercise index rating. Seventeen sufferers couldn't be included within the information evaluation, and thus intent-to-treat evaluation was primarily based on outcomes of 103 sufferers. On the finish of three months, remission charges had been 89% within the mesalamine group and 84% in E. coli Nissle 1917 group (p = 0.12). The authors concluded that E. coli Nissle 1917 was equal to mesalamine in upkeep of remission. Nonetheless, it's potential that the dose of mesalamine used was close to placebo and the examine was not adequately powered for equivalence. In 2001, Kruis et al 50 printed, in summary type, a bigger and longer period follow-up medical path than their preliminary upkeep of remission examine. There have been 327 sufferers with ulcerative colitis in medically induced remission included on this double-blind, randomized, managed examine evaluating mesalamine (Salofalk) (1.5 g per day in three divided doses) to an oral preparation of E. coli Nissle 1917 (5 × 1010 cfu per day as a single dose) for 12 months. Scientific remission was outlined utilizing the Rackmilewitz illness exercise index rating. On the finish of 12 months, remission charges had been 64% within the mesalamine group and 55% in E. coli Nissle 1917 group (p = ns). As soon as once more, the authors concluded that E. coli Nissle 1917 was equal to mesalamine within the upkeep of remission of ulcerative colitis. Venturi et al 51 examined 20 sufferers with ulcerative colitis who had been illiberal or allergic to 5-aminosalicylic acid (ASA). Sufferers had been in medical, endoscopic, and histologic remission following therapy with corticosteroids for a current acute flare throughout the earlier 3 months. Sufferers obtained open-label VSL#3 (1 × 1012 cfu each day in two divided doses) for 12 months. Sufferers had been assessed clinically each 2 months and assessed endoscopically at 6 and 12 months. On this examine, medical remission was outlined as absence of seen blood within the stools and not more than two bowel actions per day. Endoscopic remission was outlined as a rating of zero in accordance with the Baron's ulcerative colitis index. Fifteen of 20 handled sufferers (75%) remained in remission on the finish or 12 months of examine. 51 As soon as once more, vital concentrations of the probiotics current within the VSL#3 had been recognized in fecal cultures. There have been no vital adjustments in fecal focus of Bacteroides, clostridia, coliforms, or complete cardio and anaerobic micro organism.
Lastly, Ishikawa et al 52 performed a randomized, managed trial examine in 21 sufferers to look at the impact of bifidobacteria-fermented milk in sufferers with ulcerative colitis in remission. Sufferers obtained fermented milk (Yakult®, Yakult Honsha Co., Ltd, Tokyo, Japan) that contained stay bifidobacteria (Bifidobacterium breve and Bifidobacterium bifidum) and Lactobacillus acidophilus (1 × 1010 cfu per 100 mL as soon as each day) for 12 months. Remission was outlined clinically as any international enhance in signs. Compliance on the 95% stage was restricted to 7 out of 11 sufferers consuming the fermented milk product. On the finish of 12 months, medical remission was seen in 8 out of 11 topics (73%) taking the fermented milk and in 1 out of 10 topics (10%) taking placebo. 52 Curiously, regardless of this vital distinction in medical remission charges, there have been no vital variations within the colonoscopic findings at 1 yr. This raises the query as to the validity of the medical evaluation device used on this trial. Moreover, there have been no variations between the 2 teams in complete fecal bacterial counts or in bifidobacteria counts. Nonetheless, the authors had been in a position to get better (from the feces) the bifidobacteria strains current within the fermented milk. A bigger, multicenter examine with this probiotic product is at present underway.Genetically Engineered Probiotics
Not too long ago, murine interleukin (IL)-10 synthesis and secretion by genetically modified Lactococcus lactis was proven to be an environment friendly strategy to ship excessive concentrations of this anti-inflammatory cytokine. 53 When these Lactococcus lactis had been administered to murine experimental fashions of IBD, IL-10 was delivered to the mucosal floor at a focus that lowered or prevented the onset of enterocolitis. 54 These research launched new and thrilling proof of the flexibility to merge cytokine remedy for IBD with genetic engineering of probiotics. The security points associated to the genetic modification of this probiotic have been addressed by changing the thy-midylate synthase gene within the Lactococcus lactis with an artificial human IL-10 gene. This thymidylate synthase destructive, human IL-10 constructive Lactococcus lactis pressure produces human IL-10. Nonetheless, when it’s disadvantaged of thymidine or thymine, the pressure will not be viable and is eradicated by the mouse physique. 55 Theoretically, this built-in biologic containment system ought to forestall accumulation of the genetically modified probiotic within the mammalian setting. At present, a pilot trial, involving people with Crohn’s illness, is underway to look at the therapeutic security and efficacy of this human IL-10 secreting Lactococcus lactis. Because the understanding of human IBD develops, the usage of micro organism as “Trojan horses” to ship a number of therapeutic brokers ought to present thrilling prospects.
Security
The outcomes of a current worldwide workshop on the protection of lactobacilli and bifidobacteria have been printed. 56 There are actually many frequent sources of publicity to probiotics, together with packaged therapeutic merchandise, fermented foodstuffs (eg, yogurt, cheese, and fermented greens), and human microflora within the oral cavity, gut, and vagina. For this reason most of the business probiotic merchandise have been formally designated as “generally regarded as safe.” There appears to be no proof that intentionally ingested lactobacilli or bifidobacteria pose any danger of an infection higher than that related to commensal strains.
Instances of an infection because of probiotics are extraordinarily uncommon; they’re estimated to symbolize between 0.05% and 0.4% of instances of infective endocarditis or bacteremia. 57,58 Over the past 30 years, 180 instances of lactobacillemia have been reported, and 69 instances of infective endocarditis have been attributed to lactobacilli. 56 In an necessary potential examine from Finland, the marked enhance seen within the consumption of probiotics by shoppers has not led to an elevated price of opportunistic an infection by these identical probiotics. 59,60 This examine offers reassurance that the introduction of probiotics as therapeutic brokers has not, and mustn’t, end in elevated charges of human infections. Certainly, many of the uncommon instances of such infections happen within the case of immunocompromised sufferers or these with critical underlying illness states. 61,–69 Clearly, the supply of probiotics to this group of sufferers ought to be approached with warning. Although a number of makes an attempt have been made to guage the elements which may predispose such severely sick sufferers to an infection by probiotics, 61,63 statistical evaluation is missing, and the variety of instances is simply too small to allow the drawing of any statistically legitimate conclusions. Research accomplished on youngsters have proven that probiotic compounds containing lactobacilli and bifidobacteria are effectively tolerated by, and secure for, this age group. 70,–72
Regardless of these reassuringly low an infection charges for wholesome people, it would nonetheless be necessary to observe probiotic therapy security via rigorous identification of infecting organisms. These identifications ought to be verified by molecular research, as physiological characterization alone is inadequate for dependable classification. For new probiotic merchandise the place the organism will not be current within the conventional food regimen, a extra aggressive security evaluation (one much like that used for pharmacologic compounds) should be adopted. Lastly, antibiotic resistance to probiotic micro organism will not be a hazard, until it renders the probiotic untreatable, as within the uncommon case of an infection. On this regard, all strains of such probiotics ought to be inclined to plenty of main antibiotics, actually to greater than two.
Abstract
The human intestine flora is a part of an exceedingly advanced ecosystem. It’s clear that people with a genetic predisposition to the event of IBD achieve this in response to the presence of luminal micro organism. Moreover, these luminal micro organism look like central not solely to the initiation, but in addition to the perpetuation of intestinal irritation. Probiotic micro organism seem to modulate plenty of the proinflammatory pathways. Understanding of the mechanisms of motion of those probiotic micro organism, particularly within the case of IBD, will allow the event of definitive standards for the choice of probiotic strains helpful for medical utility. It should additionally permit for the willpower of optimum doses, timing of administration, and synergistic combos of bacterial species. At present, useful results exerted by probiotic micro organism could also be broadly categorized as (1) these results that come up because of exercise within the massive gut and are associated to both colonization or inhibition of pathogen development, and (2) these results that come up in each the small and huge gut and are associated to enhancement of the host immune response and barrier perform via interactions with epithelial and immune cells. It’s turning into more and more clear that the functioning of the immune system, at each a systemic and a mucosal stage, might be modulated by bacterial strains within the gut. The appearance of molecular methods that permit us to quantify, determine, and decide the genomics and proteomics of luminal micro organism and probiotics will considerably advance this space of analysis. We might want to decide if the usage of a single probiotic, or the usage of combos of probiotics, current the perfect therapeutic strategy. We additionally want to higher examine dosing and colonization points. Appropriately designed, randomized, managed medical trials have clearly recognized a therapeutic position for some probiotics within the case of pouchitis. Nonetheless, the plethora of pilot, open-label, and poorly designed medical trails, as seen within the instances of Crohn’s illness and ulcerative colitis, might be learn as tending to overstate the promise of probiotics. Rigorously designed, managed medical trials should be constructed to analyze points associated to efficacy, dose, period of use, single or multi-strain formulation, and the concomitant use of prebiotics, synbiotics, and antibiotics.
Acknowledgments
Dr. Fedorak’s analysis is supported by the Canadian Institute for Well being Analysis and the Crohn’s and Colitis Basis of Canada. Dr. Madsen’s analysis is supported by the Canadian Institute for Well being Analysis, Crohn’s and Colitis Basis of Canada, and the Alberta Heritage Basis for Medical Analysis.
References
1. Marteau PR . Probiotics in medical circumstances . Clin Rev Allergy Immunol . 2002 ; 22 : 255 – 273 . 2. Marteau P , Seksik P , Jian R . Probiotics and intestinal well being results: a medical perspective. Br J Nutr . 2002 ; 88 ( suppl 1 ): S51 – S57 . ): 3. Marteau P , Boutron-Ruault MC . Dietary benefits of probiotics and prebiotics. Br J Nutr . 2002 ; 87 ( suppl 2 ): S153 – S157 . ): 4. Tuohy KM , Probert HM , Smejkal CW , et al. Utilizing probiotics and prebiotics to enhance intestine well being . Drug Discov At this time . 2003 ; 8 : 692 – 700 . 5. Bengmark S . Use of some pre-, pro- and synbiotics in critically sick sufferers . Greatest Pract Res Clin Gastroenterol . 2003 ; 17 : 833 – 848 . 6. Cummings JH , Macfarlane GT . Gastrointestinal results of prebiotics. Br J Nutr . 2002 ; 87 ( suppl 2 ): S145 – S151 . ): 7. Steidler L . Genetically engineered probiotics . Greatest Pract Res Clin Gastroenterol . 2003 ; 17 : 861 – 876 . 8. Schley PD , Area CJ . The immune-enhancing results of dietary fibres and prebiotics. Br J Nutr . 2002 ; 87 ( suppl 2 ): S221 – S230 . ): 9. Kolida S , Tuohy Ok , Gibson GR . Prebiotic results of inulin and oligofructose. Br J Nutr . 2002 ; 87 ( suppl 2 ): S193 – S197 . ): 10. McCartney AL . Utility of molecular organic strategies for learning probiotics and the intestine flora. Br J Nutr . 2002 ; 88 ( suppl 1 ): S29 – S37 . ): 11. Saavedra JM , Tschernia A . Human research with probiotics and prebiotics: medical implications. Br J Nutr . 2002 ; 87 ( suppl 2 ): S241 – S246 . ): 12. Tamboli CP , Caucheteux C , Cortot A , et al. Probiotics in inflammatory bowel illness: a essential overview . Greatest Pract Res Clin Gastroenterol . 2003 ; 17 : 805 – 820 . 13. Teitelbaum JE , Walker WA . Dietary impression of pre- and probiotics as protecting gastrointestinal organisms . Annu Rev Nutr . 2002 ; 22 : 107 – 138 . 14. Shanahan F . Turbo probiotics for IBD . Gastroenterology . 2001 ; 120 : 1297 – 1298 . 15. Shanahan F . Probiotics and inflammatory bowel illness: from fads and fantasy to info and future. Br J Nutr . 2002 ; 88 ( suppl 1 ): S5 – S9 . ): 16. Hart AL , Stagg AJ , Kamm MA . Use of probiotics within the therapy of inflammatory bowel illness . J Clin Gastroenterol . 2003 ; 36 : 111 – 119 . 17. Schultz M , Scholmerich J , Rath HC . Rationale for probiotic and antibiotic therapy methods in inflammatory bowel illnesses . Dig Dis . 2003 ; 21 : 105 – 128 . 18. Shanahan F . Inflammatory bowel illness: immunodiagnostics, immunotherapeutics, and ecotherapeutics . Gastroenterology . 2001 ; 120 : 622 – 635 . 19. Fooks LJ , Gibson GR . Probiotics as modulators of the intestine flora. Br J Nutr . 2002 ; 88 ( suppl 1 ): S39 – S49 . ): 20. Kraehenbuhl JP . Mucosatargeted DNA vaccination . Traits Immunol . 2001 ; 22 : 646 – 648 . 21. Akira S , Sato S . Toll-like receptors and their signaling mechanisms . Scand J Infect Dis . 2003 ; 35 : 555 – 562 . 22. Yamamoto M , Takeda Ok , Akira S . TIR domain-containing adaptors outline the specificity of TLR signaling . Mol Immunol . 2004 ; 40 : 861 – 868 . 23. Di Marzio L , Russo FP , D’Alo S , et al. Apoptotic results of chosen strains of lactic acid micro organism on a human T leukemia cell line are related to bacterial arginine deiminase and/or sphingomyelinase actions . Nutr Most cancers . 2001 ; 40 : 185 – 196 . 24. Madsen Ok , Cornish A , Soper P , et al. Probiotic micro organism improve murine and human intestinal epithelial barrier perform . Gastroenterology . 2001 ; 121 : 580 – 591 . 25. Anton P , O’Connell J , O’Connell D , et al. Mucosal subepithelial binding websites for the bacterial chemotactic peptide, formyl-methionyl-leucyl-phenylalanine (FMLP) . Intestine . 1998 ; 42 : 374 – 379 . 26. Girardin SE , Travassos LH , Herve M , et al. Peptidoglycan molecular necessities permitting detection by Nod1 and Nod2 . J Biol Chem . 2003 ; 278 : 41702 – 41708 . 27. Inohara N , Ogura Y , Fontalba A , et al. Host recognition of bacterial muramyl dipeptide mediated via NOD2. Implications for Crohn’s illness. J Biol Chem . 2003 ; 278 : 5509 – 5512 . 28. Chamaillard M , Hashimoto M , Horie Y , et al. A vital position for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid . Nat Immunol . 2003 ; 4 : 702 – 707 . 29. Madsen Ok , Jijon H , Yeung H , et al. DNA from probiotic micro organism exerts anti-inflammatory actions on intestinal epithelial cells by inhibition of NF-kB . Gastroenterology . 2002 ; 122 : A546 . 30. Akhtar M , Watson JL , Nazli A , et al. Bacterial DNA evokes epithelial IL-8 manufacturing by a MAPK-dependent, NF-kappaB-independent pathway . FASEB J . 2003 ; 17 : 1319 – 1321 . 31. Rachmilewitz D , Karmeli F , Takabayashi Ok , et al. Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis . Gastroenterology . 2002 ; 122 : 1428 – 1441 . 32. Ruselervan Embden JG , Schouten WR , van Lieshout LM .
Pouchitis
: results of microbial imbalance? Intestine . 1994 ; 35 : 658 – 664 . 33. Gionchetti P , Rizzello F , Venturi A , et al. Oral bacteriotherapy as upkeep therapy in sufferers with persistent pouchitis: a double-blind, placebo-controlled trial . Gastroenterology . 2000 ; 119 : 305 – 309 . 34. Mimura T , Rizzello F , Schreiber S , et al. As soon as each day excessive dose probiotic remedy maintains remission and improved high quality of life in sufferers with recurrent or refractory pouchitis: a randomised, placebo-controlled, double-blind trial . Complement to Gastroenterology . 2002 ; 122 : A81 . 35. Kuisma J , Mentula S , Jarvinen H , et al. Impact of Lactobacillus rhamnosus GG on ileal pouch irritation and microbial flora . Aliment Pharmacol Ther . 2003 ; 17 : 509 – 515 . 36. Laake KO , Line PD , Aabakken L , et al. Evaluation of mucosal irritation and circulation in response to probiotics in sufferers operated with ileal pouch anal anastomosis for ulcerative colitis . Scand J Gastroenterol . 2003 ; 38 : 409 – 414 . 37. Gionchetti P , Rizzello F , Helwig U , et al. Prophylaxis of pouchitis onset with probiotic remedy: a double-blind, placebo-controlled trial . Gastroenterology . 2003 ; 124 : 1202 – 1209 . 38. Gupta P , Andrew H , Kirschner BS , et al. Is lactobacillus GG useful in youngsters with Crohn’s illness? Outcomes of a preliminary, open-label examine . J Pediatr Gastroenterol Nutr . 2000 ; 31 : 453 – 457 . 39. McCarthy J , O’Mahony L , Dunne C , et al. An open trial of a novel probiotic as an alternative choice to steroids in delicate/reasonably lively Crohn’s illness. Intestine . 2001 ;49(suppl III): 2447 . ;49(suppl III): 40. Malchow HA . Crohn’s illness and Escherichia coli . A brand new strategy in remedy to keep up remission of colonic Crohn’s illness? J Clin Gastroenterol . 1997 ; 25 : 653 – 658 . 41. Guslandi M , Mezzi G , Sorghi M , et al. Saccharomyces boulardii in upkeep therapy of Crohn’s illness . Dig Dis Sci . 2000 ; 45 : 1462 – 1464 . 42. Prantera C , Scribano ML , Falasco G , et al. Ineffectiveness of probiotics in stopping recurrence after healing resection for Crohn’s illness: a randomised managed trial with Lactobacillus GG . Intestine . 2002 ; 51 : 405 – 409 . 43. Campieri M , Rizzello F , Venturi A , et al. Mixture of antibiotic and probiotic therapy is efficacious in prophylaxis of post-operative recurrence of Crohn’s illness: a randomized managed examine vs mesalamine . Gastroenterology . 2000 ; 118 : A781 . 44. Rutgeerts P , Hiele M , Geboes Ok , et al. Managed trial of metronidazole therapy for prevention of Crohn’s recurrence after ileal resection . Gastroenterology . 1995 ; 108 : 1617 – 1621 . 45. Rembacken BJ , Snelling AM , Hawkey PM , et al. Non-pathogenic Escherichia coli versus mesalazine for the therapy of ulcerative colitis: a randomised trial . Lancet . 1999 ; 354 : 635 – 639 . 46. Fedorak RN , Gionchetti P , Campieri M , et al. VSL3 Probiotic combination induces remission in sufferers with lively ulcerative colitis . Gastroenterology . 2003 ; 124 : A377 . 47. Guslandi M , Giollo P , Testoni PA . A pilot trial of Saccharomyces boulardii in ulcerative colitis . Eur J Gastroenterol Hepatol . 2003 ; 15 : 697 – 698 . 48. Borody TJ , Warren EF , Leis S , et al. Remedy of ulcerative colitis utilizing fecal bacteriotherapy . J Clin Gastroenterol . 2003 ; 37 : 42 – 47 . 49. Kruis W , Schutz E , Fric P , et al. Double-blind comparability of an oral Escherichia coli preparation and mesalazine in sustaining remission of ulcerative colitis . Aliment Pharmacol Ther . 1997 ; 11 : 853 – 858 . 50. Kruis W , Fric P , Stolte M . Upkeep of remission in ulcerative colitis is equality efficient with Escherichia coli Nissle 1917 and with customary mesalamine. Gastroenterology . 2001 ; 120 : A127 . 51. Venturi A , Gionchetti P , Rizzello F , et al. Affect on the composition of the faecal flora by a brand new probiotic preparation: preliminary information on upkeep therapy of sufferers with ulcerative colitis . Aliment Pharmacol Ther . 1999 ; 13 : 1103 – 1108 . 52. Ishikawa H , Akedo I , Umesaki Y , et al. Randomized managed trial of the impact of bifidobacteria-fermented milk on ulcerative colitis . J Am Coll Nutr . 2003 ; 22 : 56 – 63 . 53. Schotte L , Steidler L , Vandekerckhove J , et al. Secretion of biologically lively murine interleukin-10 by Lactococcus lactis . Enzyme Microb Technol . 2000 ; 27 : 761 – 765 . 54. Steidler L , Hans W , Schotte L , et al. Remedy of murine colitis by Lactococcus lactis secreting interleukin-10 . Science . 2000 ; 289 : 1352 – 1355 . 55. Steidler L , Neirynck S , Huyghebaert N , et al. Organic containment of genetically modified Lactococcus lactis for intestinal supply of human interleukin 10 . Nat Biotechnol . 2003 ; 21 : 785 – 789 . 56. Borriello SP , Hammes WP , Holzapfel W , et al.
Security
of probiotics that include lactobacilli or bifidobacteria . Clin Infect Dis . 2003 ; 36 : 775 – 780 . 57. Gasser F .
Security
of lactic-acid micro organism and their prevalence in human medical infections. Bulletin de L’Institut Pasteur . 1994 ; 92 : 45 – 67 . 58. Saxelin M , Chuang NH , Chassy B , et al. Lactobacilli and bacteremia in southern Finland, 1989-1992 . Clin Infect Dis . 1996 ; 22 : 564 – 566 . 59. Salminen MK , Tynkkynen S , Rautelin H , et al. Lactobacillus bacteremia throughout a fast enhance in probiotic use of Lactobacillus rhamnosus GG in Finland . Clin Infect Dis . 2002 ; 35 : 1155 – 1160 . 60. Statistics Finland . Finland in figures. Helsinki: Library of Statistics. 2000. . Finland in figures. Helsinki: Library of Statistics. 2000. 61. Husni RN , Gordon SM , Washington JA , et al. Lactobacillus bacteremia and endocarditis: overview of 45 instances . Clin Infect Dis . 1997 ; 25 : 1048 – 1055 . 62. Wolf BW , Wheeler KB , Ataya DG , et al.
Security
and tolerance of Lacto-bacillus reuteri supplementation to a inhabitants contaminated with the human immunodeficiency virus . Meals Chem Toxicol . 1998 ; 36 : 1085 – 1094 . 63. Patel R , Cockerill FR , Porayko MK , et al. Lactobacillemia in liver transplant sufferers . Clin Infect Dis . 1994 ; 18 : 207 – 212 . 64. Antony SJ , Stratton CW , Dummer JS . Lactobacillus bacteremia: description of the medical course in grownup sufferers with out endocarditis . Clin Infect Dis . 1996 ; 23 : 773 – 778 . 65. Piarroux R , Millon L , Bardonnet Ok , et al. Are stay saccharomyces yeasts dangerous to sufferers? Lancet . 1999 ; 353 : 1851 – 1852 . 66. Rautio M , Jousimies-Somer H , Kauma H , et al. Liver abscess because of a Lactobacillus rhamnosus pressure indistinguishable from L. rhamnosus pressure GG. Clin Infect Dis . 1999 ; 28 : 1159 – 1160 . 67. Pletincx M , Legein J , Vandenplas Y . Fungemia with Saccharomyces boulardii in a 1-year-old woman with protracted diarrhea . J Pediatr Gastroenterol Nutr . 1995 ; 21 : 113 – 115 . 68. Horwitch CA , Furseth HA , Larson AM , et al. Lactobacillemia in three sufferers with AIDS . Clin Infect Dis . 1995 ; 21 : 1460 – 1462 . 69. Chomarat M , Espinouse D . Lactobacillus rhamnosus septicemia in sufferers with extended aplasia receiving ceftazidime-vancomycin. Eur J Clin Microbiol Infect Dis . 1991 ; 10 : 44 . 70. Pedone CA , Bernabeu AO , Postaire ER , et al. The impact of supplementation with milk fermented by Lactobacillus casei (pressure DN-114 001) on acute diarrhoea in youngsters attending day care centres . Int J Clin Pract . 1999 ; 53 : 179 – 184 . 71. Vanderhoof JA , Younger RJ . Use of probiotics in childhood gastrointestinal problems . J Pediatr Gastroenterol Nutr . 1998 ; 27 : 323 – 332 . 72. Guandalini S , Pensabene L , Zikri MA , et al. Lactobacillus GG administered in oral rehydration resolution to youngsters with acute diarrhea: a multicenter European trial . J Pediatr Gastroenterol Nutr . 2000 ; 30 : 54 – 60 . 73. Resta-Lenert S , Barrett KE . Stay probiotics shield intestinal epithelial cells from the results of an infection with enteroinvasive Escherichia coli (EIEC) . Intestine . 2003 ; 52 : 988 – 997 . 74. Ouwehand AC , Lagstrom H , Suomalainen T , et al. Impact of probiotics on constipation, fecal azoreductase exercise and fecal mucin content material within the aged. Ann Nutr Metab 2002 ;46(3-4): 159 – 162 . ;46(3-4): 75. Mack DR , Ahrne S , Hyde L , et al. Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro . Intestine . 2003 ; 52 : 827 – 833 . 76. Lievin-Le Moal V , Amsellem R , Servin AL , et al. Lactobacillus acidophilus (pressure LB) from the resident grownup human gastrointestinal micro-flora exerts exercise in opposition to brush border harm promoted by a diarrhoeagenic Escherichia coli in human enterocyte-like cells . Intestine . 2002 ; 50 : 803 – 811 . 77. Garcia-Lafuente A , Antolin M , Guarner F , et al. Modulation of colonic barrier perform by the composition of the commensal flora within the rat . Intestine . 2001 ; 48 : 503 – 507 . 78. Freitas M , Tavan E , Cayuela C , et al. Host-pathogens cross-talk. Indigenous micro organism and probiotics additionally play the sport. Biol Cell . 2003 ; 95 : 503 – 506 . 79. Kaila M , Isolauri E , Soppi E , et al. Enhancement of the circulating antibody secreting cell response in human diarrhea by a human Lactobacillus pressure . Pediatr Res . 1992 ; 32 : 141 – 144 . 80. Majamaa H , Isolauri E , Saxelin M , et al. Lactic acid micro organism within the therapy of acute rotavirus gastroenteritis . J Pediatr Gastroenterol Nutr . 1995 ; 20 : 333 – 338 . 81. Fang H , Elina T , Heikki A , et al. Modulation of humoral immune response via probiotic consumption . FEMS Immunol Med Microbiol . 2000 ; 29 : 47 – 52 . 82. Gill HS , Cross ML , Rutherfurd KJ , et al. Dietary probiotic supplementation to reinforce mobile immunity within the aged . Br J Biomed Sci . 2001 ; 58 : 94 – 96 . 83. Cano PG , Aguero G , Perdigon G . Immunological results of yogurt addition to a re-nutrition food regimen in a malnutrition experimental mannequin . J Dairy Res . 2002 ; 69 : 303 – 316 . 84. Park JH , Um JI , Lee BJ , et al. Encapsulated Bifidobacterium bifidum potentiates intestinal IgA manufacturing . Cell Immunol . 2002 ; 219 : 22 – 27 . 85. Shu Q , Gill HS . Immune safety mediated by the probiotic Lactobacillus rhamnosus HN001 (DR20) in opposition to Escherichia coli O157:H7 an infection in mice . FEMS Immunol Med Microbiol . 2002 ; 34 : 59 – 64 . 86. Braat H , De Jong EC , Van Den Brande JM , et al. Dichotomy between Lactobacillus rhamnosus and Klebsiella pneumoniae on dendritic cell phenotype and performance . J Mol Med . 2004 ; 82 : 197 – 205 . 87. Curler M , Rechkemmer G , Watzl B . Prebiotic inulin enriched with oligofructose together with the probiotics Lactobacillus rhamnosus and Bifidobacterium lactis modulates intestinal immune features in rats . J Nutr . 2004 ; 134 : 153 – 156 . 88. Neish AS , Gewirtz AT , Zeng H , et al. Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination . Science . 2000 ; 289 : 1560 – 1563 . 89. Yan F , Polk DB . Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells . J Biol Chem . 2002 ; 277 : 50959 – 50965 . 90. Kullisaar T , Zilmer M , Mikelsaar M , et al. Two antioxidative lactobacilli strains as promising probiotics . Int J Meals Microbiol . 2002 ; 72 : 215 – 224 . 91. He F , Ouwehand AC , Isolauri E , et al. Comparability of mucosal adhesion and species identification of bifidobacteria remoted from wholesome and allergic infants . FEMS Immunol Med Microbiol . 2001 ; 30 : 43 – 47 . 92. Lee YK , Puong KY . Competitors for adhesion between probiotics and human gastrointestinal pathogens within the presence of carbohydrate. Br J Nutr . 2002 ; 88 ( suppl 1 ): S101 – S108 . ): 93. Boudeau J , Glasser AL , Julien S , et al. Inhibitory impact of probiotic Escherichia coli pressure Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent-invasive E. coli strains remoted from sufferers with Crohn’s illness . Aliment Pharmacol Ther . 2003 ; 18 : 45 – 56 . 94. Fernandez MF , Boris S , Barbes C . Probiotic properties of human lacto-bacilli strains for use within the gastrointestinal tract . J Appl Microbiol . 2003 ; 94 : 449 – 455 . 95. Huang Y , Adams MC . An in vitro mannequin for investigating intestinal adhesion of potential dairy propionibacteria probiotic strains utilizing cell line C2BBe1 . Lett Appl Microbiol . 2003 ; 36 : 213 – 216 . 96. Kos B , Suskovic J , Vukovic S , et al. Adhesion and aggregation skill of probiotic pressure Lactobacillus acidophilus M92 . J Appl Microbiol . 2003 ; 94 : 981 – 987 . 97. Lee YK , Puong KY , Ouwehand AC , et al. Displacement of bacterial pathogens from mucus and Caco-2 cell floor by lactobacilli . J Med Microbiol . 2003 ; 52 : 925 – 930 . 98. Rinkinen M , Jalava Ok , Westermarck E , et al. Interplay between probiotic lactic acid micro organism and canine enteric pathogens: a danger issue for intestinal Enterococcus faecium colonization? Vet Microbiol . 2003 ; 92 (1-2): 111 – 119 . (1-2): 99. Schaer-Zammaretti P , Ubbink J . Imaging of lactic acid micro organism with AFM—elasticity and adhesion maps and their relationship to organic and structural information. Ultramicroscopy . 2003 ;97(1-4): 199 – 208 . ;97(1-4): 100. Michail S , Abernathy F . Lactobacillus plantarum reduces the in vitro secretory response of intestinal epithelial cells to enteropathogenic Escherichia coli an infection . J Pediatr Gastroenterol Nutr . 2002 ; 35 : 350 – 355 . 101. Hashizume Ok , Tsukahara T , Yamada Ok , et al. Megasphaera elsdenii JCM1772T normalizes hyperlactate manufacturing within the massive gut of fructooligosaccharide-fed rats by stimulating butyrate manufacturing . J Nutr . 2003 ; 133 : 3187 – 3190 . 102. Coconnier MH , Lievin V , Lorrot M , et al. Antagonistic exercise of Lactobacillus acidophilus LB in opposition to intracellular Salmonella enterica serovar Typhimurium infecting human enterocyte-like Caco-2/TC-7 cells . Appl Environ Microbiol . 2000 ; 66 : 1152 – 1157 . 103. Lievin V , Peiffer I , Hudault S , et al. Bifidobacterium strains from resident toddler human gastrointestinal microflora exert antimicrobial exercise . Intestine . 2000 ; 47 : 646 – 652 . 104. Caridi A . Collection of Escherichia coli-inhibiting strains of Lactobacillus paracasei subsp. paracasei . J Ind Microbiol Biotechnol . 2002 ; 29 : 303 – 308 . 105. Eijsink VG , Axelsson L , Diep DB , et al. Manufacturing of sophistication II bacteriocins by lactic acid micro organism; an instance of organic warfare and communication. Antonie Van Leeuwenhoek . 2002 ;81(1-4): 639 – 654 . ;81(1-4): 106. Flynn S , van Sinderen D , Thornton GM , et al. Characterization of the genetic locus answerable for the manufacturing of ABP-118, a novel bacteriocin produced by the probiotic bacterium Lactobacillus salivarius subsp. salivarius UCC118 . Microbiology . 2002 ; 148 : 973 – 984 . 107. Park SH , Itoh Ok , Fujisawa T . Traits and identification of enterocins produced by Enterococcus faecium JCM 5804T . J Appl Microbiol . 2003 ; 95 : 294 – 300 . 108. Xiao H , Chen X , Chen M , et al. Bovicin HJ50, a novel lantibiotic produced by Streptococcus bovis HJ50 . Microbiology . 2004 ; 150 : 103 – 108 . 109. Kato I , Endo-Tanaka Ok , Yokokura T . Suppressive results of the oral administration of Lactobacillus casei on sort II collagen-induced arthritis in DBA/1 mice . Life Sci . 1998 ; 63 : 635 – 644 . 110. Madsen KL , Doyle JS , Jewell LD , et al. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice . Gastroenterology . 1999 ; 116 : 1107 – 1114 . 111. Haller D , Bode C , Hammes WP , et al. Non-pathogenic micro organism elicit a differential cytokine response by intestinal epithelial cell/leucocyte co-cultures . Intestine . 2000 ; 47 : 79 – 87 . 112. Maassen CB , van Holten-Neelen C , Balk F , et al. Pressure-dependent induction of cytokine profiles within the intestine by orally administered Lactobacillus strains . Vaccine . 2000 ; 18 : 2613 – 2623 . 113. Kalliomaki M , Salminen S , Arvilommi H , et al. Probiotics in main prevention of atopic illness: a randomised placebo-controlled trial . Lancet . 2001 ; 357 : 1076 – 1079 . 114. von der Weid T , Bulliard C , Schiffrin EJ . Induction by a lactic acid bacterium of a inhabitants of CD4(+) T cells with low proliferative capability that produce reworking development issue beta and interleukin-10 . Clin Diagn Lab Immunol . 2001 ; 8 : 695 – 701 . 115. He F , Morita H , Ouwehand AC , et al. Stimulation of the secretion of pro-inflammatory cytokines by Bifidobacterium strains . Microbiol Immunol . 2002 ; 46 : 781 – 785 . 116. Lammers KM , Helwig U , Swennen E , et al. Impact of probiotic strains on interleukin 8 manufacturing by HT29/19A cells . Am J Gastroenterol . 2002 ; 97 : 1182 – 1186 . 117. Morita H , He F , Fuse T , et al. Adhesion of lactic acid micro organism to caco-2 cells and their impact on cytokine secretion . Microbiol Immunol . 2002 ; 46 : 293 – 297 . 118. Morita H , He F , Fuse T , et al. Cytokine manufacturing by the murine macrophage cell line J774.1 after publicity to lactobacilli . Biosci Biotechnol Biochem . 2002 ; 66 : 1963 – 1966 . 119. Perdigon G , Maldonado Galdeano C , Valdez JC , et al. Interplay of lactic acid micro organism with the intestine immune system. Eur J Clin Nutr . 2002 ; 56 ( suppl 4 ): S21 – S26 . ): 120. Lammers KM , Brigidi P , Vitali B , et al. Immunomodulatory results of probiotic micro organism DNA: IL-1 and IL-10 response in human peripheral blood mononuclear cells . FEMS Immunol Med Microbiol . 2003 ; 38 : 165 – 172 . 121. McCarthy J , O’Mahony L , O’Callaghan L , et al. Double blind, placebo managed trial of two probiotic strains in interleukin 10 knockout mice and mechanistic hyperlink with cytokine stability . Intestine . 2003 ; 52 : 975 – 980 . 122. Schultz M , Linde HJ , Lehn N , et al. Immunomodulatory penalties of oral administration of Lactobacillus rhamnosus pressure GG in wholesome volunteers . J Dairy Res . 2003 ; 70 : 165 – 173 . 123. Vinderola CG , Medici M , Perdigon G . Relationship between interplay websites within the intestine, hydrophobicity, mucosal immunomodulating capacities and cell wall protein profiles in indigenous and exogenous micro organism . J Appl Microbiol . 2004 ; 96 : 230 – 243 . 124. Prioult G , Fliss I , Pecquet S . Impact of probiotic micro organism on induction and upkeep of oral tolerance to beta-lactoglobulin in gnotobiotic mice . Clin Diagn Lab Immunol . 2003 ; 10 : 787 – 792 . 125. Gionchetti P , Amadini C , Rizzello F , et al. Evaluate article: therapy of delicate to average ulcerative colitis and pouchitis. Aliment Pharmacol Ther . 2002 ; 16 ( suppl 4 ): 13 – 19 . ):
Creator notes
Copyright © 2004 by Lippincott Williams & Wilkins.